Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.14)
# 1,155
Out of 5,157 analysts
6
Total ratings
60%
Success rate
100.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.94 | +6.86% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $4 | $0.31 | +1,190.32% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $4.85 | +3.09% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $16.93 | +41.80% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $2.38 | +152.10% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.68 | +1,825.93% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.94
Upside: +6.86%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $4
Current: $0.31
Upside: +1,190.32%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $4.85
Upside: +3.09%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $16.93
Upside: +41.80%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.68
Upside: +1,825.93%